PAREXEL Strengthens Executive Leadership with Appointments of Roland Andersson, Ph.D. and Thomas Senderovitz, M.D. as Senior Vice Presidents of Clinical Research Services
BOSTON, MA, April 7, 2014 – PAREXEL International (NASDAQ: PRXL), a leading global biopharmaceutical services organization, today announced Dr. Roland Andersson, Ph.D., and Dr. Thomas Senderovitz, M.D., as Senior Vice Presidents in the Company’s Clinical Research Services (CRS) strategic business unit. The executives will be centrally involved in developing and implementing PAREXEL’s global corporate objectives.
"Roland Andersson and Thomas Senderovitz further strengthen our CRS senior leadership team with a breadth of biopharmaceutical experience, industry knowledge, and proven strategic guidance,” said Mark A. Goldberg, M.D., President and Chief Operating Officer, PAREXEL. “Under their collective leadership, we are well positioned to expand our global CRS infrastructure and innovate in ways that help simplify clients’ drug development journeys.”
Dr. Andersson will have overall responsibility for the management of PAREXEL’s Phase II-III client relationships on a global basis, including strategic accounts and the Company’s Biopharm Unit that focuses on the needs of small and emerging companies. He has extensive experience leading and transforming businesses within the biotechnology, pharmaceutical and medical device sectors. His primary expertise is in research and development management, transformation, strategy, and business development. Prior to joining PAREXEL, Dr. Andersson served as managing director at Accenture, where he oversaw technology, consulting and business services for leading pharmaceutical and biotech companies. While at Accenture, he played a pivotal role in creating TransCelerate BioPharma, an industry group that aligns the world’s best-known biopharmaceutical companies to address common drug development problems. Dr. Andersson received an MS in Engineering and a Ph.D. in Management from Linköping Institute of Technology, Sweden.
Dr. Senderovitz will have global management responsibility for PAREXEL’s Early Phase and Clinical Logistics business units, as well as the Global Medical Services function. He joins the Company from Grunenthal, an international research-based pharmaceutical company headquartered in Germany, where he served as executive vice president of Global Compound Development. At Grunenthal, Dr. Senderovitz provided strategic development and project oversight for all clinical development functions, including Early Clinical Development, Late Stage Clinical Development, Global Clinical Operations, and Global Biometrics. Before joining Grünenthal, Dr. Senderovitz was Vice President of Global Exploratory Development at UCB and Vice President of Clinical R&D at Ferring Pharmaceuticals. He received his M.D. from the Faculty of Medicine at the University of Copenhagen.
# # #
About PAREXEL International
PAREXEL International Corporation is a leading global biopharmaceutical services organization, providing a broad range of knowledge-based contract research, consulting, medical communications, and technology solutions and services to the worldwide pharmaceutical, biotechnology and medical device industries. Committed to providing solutions that expedite time-to-market and peak-market penetration, PAREXEL has developed significant expertise across the development and commercialization continuum, from drug development and regulatory consulting to clinical pharmacology, clinical trials management, medical education and reimbursement. PAREXEL Informatics, Inc., a subsidiary of PAREXEL, provides advanced technology solutions, including medical imaging, to facilitate the clinical development process. Headquartered near Boston, Massachusetts, PAREXEL operates in 76 locations in 50 countries around the world, and has 15,100 employees. For more information about PAREXEL International visit www.PAREXEL.com.
PAREXEL and “Your Journey. Our Mission.” are trademarks or registered trademarks of PAREXEL International Corporation or its affiliates.
This release contains “forward-looking” statements regarding future results and events, including, without limitation, statements regarding expected financial results, future growth and customer demand. For this purpose, any statements contained herein that are not statements of historical fact may be deemed forward-looking statements. Without limiting the foregoing, the words “believes,” “anticipates,” “plans,” “expects,” “intends,” “appears,” “estimates,” “projects,” “will,” “would,” “could,” “should,” “targets,” and similar expressions are also intended to identify forward-looking statements. The forward-looking statements in this release involve a number of risks and uncertainties. The Company’s actual future results may differ significantly from the results discussed in the forward-looking statements contained in this release. Important factors that might cause such a difference include, but are not limited to, risks associated with: actual operating performance; actual expense savings and other operating improvements resulting from recent and anticipated restructurings; the loss, modification, or delay of contracts which would, among other things, adversely impact the Company’s recognition of revenue included in backlog; the Company’s dependence on certain industries and clients; the Company’s ability to win new business, manage growth and costs, and attract and retain employees; the Company’s ability to complete additional acquisitions, and to integrate newly acquired businesses including the recent acquisitions of LIQUENT, Inc. and HERON, Inc., or enter into new lines of business; the impact on the Company’s business of government regulation of the drug, medical device and biotechnology industry; consolidation within the pharmaceutical industry and competition within the biopharmaceutical services industry; the potential for significant liability to clients and third parties; the potential adverse impact of health care reform; and the effects of exchange rate fluctuations and other international economic, political, and other risks. Such factors and others are discussed more fully in the section entitled “Risk Factors” of the Company’s Quarterly Report on Form 10-Q for the fiscal quarter ended December 31, 2013 as filed with the SEC on January 31, 2014, which “Risk Factors” discussion is incorporated by reference in this press release. The Company specifically disclaims any obligation to update these forward-looking statements in the future. These forward-looking statements should not be relied upon as representing the Company’s estimates or views as of any date subsequent to the date of this press release.